Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 43, 31, 2, 89, 58 and 3 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 14, 5 and 1 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

2N Pharma ApS
AbbVie Inc
Acadia Pharmaceuticals Inc
Actinogen Medical Ltd
AcuraStem Inc
Adamed Pharma SA
ADEL Inc
AFFiRiS AG
AgeneBio Inc
AIBIOS Co Ltd
Alector Inc
Alkermes Plc
AlphaCognition Inc
Alterity Therapeutics Ltd
Alzamend Neuro Inc
Amarantus Bioscience Holdings Inc
Anavex Life Sciences Corp
Anhorn Medicines Co Ltd
Annovis Bio Inc
Aphios Corp
Applied Genetic Technologies Corp
Aprinoia Therapeutics Inc
Aptinyx Inc
AriBio
Arkuda Therapeutics Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asceneuron SA
AskAt Inc
Astrogen Ltd
Athira Pharma Inc
AULBIO Co Ltd
Aurum Biosciences Ltd
Autifony Therapeutics Ltd
Avanir Pharmaceuticals Inc
AviadoBio Ltd
Avineuro Pharmaceuticals Inc
Avrion Therapeutics AG
Axon Neuroscience SE
Axsome Therapeutics Inc
Bioasis Technologies Inc
Biogen Inc
Biom Therapeutics LLC
Biorchestra Co Ltd
BioXcel Therapeutics Inc
CAMP4 Therapeutics Corp
Cellivery Therapeutics Inc
Cellular Biomedicine Group Ltd
Cennerv Pharma (S) Pte Ltd
Cerevel Therapeutics Holdings Inc
ChunLab Inc
Cogentis Therapeutics Inc
Cognition Therapeutics Inc
Cortice Biosciences Inc
Coya Therapeutics Inc
CSPC NBP Pharmaceutical Co Ltd
CuraSen Therapeutics Inc
Cyclerion Therapeutics Inc
Dadang & BIO Co Ltd
Daewoong Pharmaceutical Co Ltd
Denali Therapeutics Inc
DiaMedica Therapeutics Inc
Dongkook Pharmaceutical Co Ltd
Dr. August Wolff GmbH & Co KG Arzneimittel
Echo Pharmaceuticals BV
EIP Pharma LLC
Eisai Co Ltd
Eli Lilly and Co
ENCEFA
Ensol Biosciences Inc
Enterin Inc
EVER Neuro Pharma GmbH
Expansion Therapeutics Inc
Galimedix Therapeutics Ltd
Generian Pharmaceuticals Inc
Gismo Therapeutics Inc
GraySpace Therapeutics Inc
Guangzhou Magpie Pharmaceutical Co Ltd
HanAll Biopharma Co Ltd
Hemostemix Inc
Herophilus
HLB Pharmaceutical Co Ltd
Hyundai Pharma Co Ltd
IGC Pharma LLC
Immungenetics AG
ImStar Therapeutics Inc
Inhibikase Therapeutics Inc
Intra-Cellular Therapies Inc
IntraBio Ltd
Inventage Lab Inc
Ionis Pharmaceuticals Inc
IRLAB Therapeutics AB
Jazz Pharmaceuticals Plc
Johnson & Johnson
KeifeRx LLC
Kogenix Therapeutics Inc
Korea Pharma Co Ltd
Kuano Ltd
Kwang Dong Pharmaceutical Co Ltd
Lachesis Biosciences Ltd
Locanabio Inc
Luye Pharma Group Ltd
MediPost Co Ltd
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Metro International Biotech LLC
MGC Pharmaceuticals Ltd
MThera Pharma Co Ltd
MYND Life Sciences Inc
Neuramedy Co Ltd
Neurimmune Holding AG
Neurokine Therapeutics
NeuroScientific Biopharmaceuticals Ltd
NeuroTau Inc
Neuvivo Inc
NLS Pharmaceutics AG
Novartis AG
Novo Nordisk AS
Oligomerix inc
Orchard Therapeutics Plc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
P2D Inc
Pacific Northwest Biotechnology LLC
Palisades Therapeutics
Park of Active Molecules
Passage Bio Inc
Plico Biotech Inc
Prediction BioSciences SAS
ProMIS Neurosciences Inc
Prothena Corp Plc
Psy Therapeutics Inc
PurMinds NeuroPharma Inc
QurAlis Corporation
Reata Pharmaceuticals Inc
Reborna Biosciences Inc
Resverlogix Corp
Reven Holdings Inc
Rubedo Life Sciences Inc
Sage Therapeutics Inc
Samus Therapeutics Inc
Shaperon Inc
Sinfonia Biotherapeutics Inc
Sio Gene Therapies Inc
SK Chemicals Co Ltd
SOLA Biosciences LLC
Stealth BioTherapeutics Corp
Stemedica Cell Technologies Inc
Sun Pharma Advanced Research Company Ltd
Suven Life Sciences Ltd
SyneuRx International Corp
T3D Therapeutics Inc
Targeted Pharmaceuticals LLC
TauRx Therapeutics Ltd
Teitur Trophics ApS
Theranexus SAS
Time Therapeutics Inc
Towa Pharmaceutical Co Ltd
Tranquis Therapeutics Inc
Transposon Therapeutics Inc
UCB SA
UniQure NV
Unity Biotechnology Inc
Vanqua Bio Inc
Vaxxinity Inc
Verge Genomics Inc
Voyager Therapeutics Inc
Wave Life Sciences Ltd
Whan In Pharm Co Ltd
Yumanity Therapeutics Inc